> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Inhibrx Biosciences Stock Plunges 7% After Higher Borrowing Costs Widen Its Quarterly Loss
- URL: https://www.bullished.co/inhibrx-biosciences-stock-plunges-7-after-higher-borrowing-costs-widen-its-quarterly-loss-dc5077bc/
- Published: 2026-11-16T18:28:12.000Z
- Updated: 2026-11-16T18:28:12.000Z
- Description: The cancer-treatment developer cut research spending, but its loan balance rose to $275 million from $100 million a year earlier.
- Author: Matteo Parrino
- Tags: Markets, INBX, Industry: Healthcare

[Inhibrx Biosciences](https://www.bullished.co/tag/inbx/), which develops experimental biologic therapies, plunged 7.4% to $77.18 in Monday trading, as of 1:26 PM ET, erasing $90 million in market value. The decline followed Friday's results: a [net loss](https://www.sec.gov/Archives/edgar/data/0002007919/000200791926000057/inhibrx-20261113.htm?ref=bullished.co) of $38.7 million for the quarter, up from $35.3 million a year earlier, which the company attributed to higher borrowing costs.

## A Bigger Loan Bill

Inhibrx's loan balance reached $275 million, compared with $100 million a year earlier. The company identified interest on that balance as the main reason other expenses climbed to $7 million from $1.4 million.

Research spending fell to [$26 million](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000059/inhibrx-20260930.htm?ref=bullished.co) from $28.5 million a year earlier. Management attributed the reduction mainly to cheaper trials and fewer employees.

Administrative spending rose as Inhibrx prepared for a potential launch of its chondrosarcoma treatment. The company ended September with [$199.5 million](https://www.sec.gov/Archives/edgar/data/0002007919/000200791926000057/inhibrx-20261113.htm?ref=bullished.co) in cash and equivalents.

## Five Declines In A Row

The stock was on pace Monday for its fifth straight daily decline. Its market value stood at $1.1 billion in Monday trading.

Inhibrx shares were up 5% for the year at Friday's close, trailing the S&P 500's 11% gain. Even with that positive return, the shares ended Friday 41% below their highest close of the past year.

## Cancer Programs Still In Trials

Inhibrx has no approved products. Its business centers on two cancer programs in clinical trials, using its own protein-engineering platforms to build biologic treatment candidates.

Ozekibart targets DR5, a receptor involved in cell death, and is being studied in chondrosarcoma, Ewing sarcoma, colorectal cancer and other solid tumors. INBRX-106 targets OX40, an immune-cell receptor, and is being tested alone and with Merck's Keytruda in non-small cell lung cancer and head and neck squamous cell carcinoma.

Inhibrx became a stand-alone public company through a May 2024 spin-off from its former parent. As of December 31, 2025, it solely owned 31 patent families.

Inhibrx expects initial results around mid-2027 from its expanded ordastobart head-and-neck cancer study, with FDA discussions and a planned late-stage confirmatory trial to follow.

### Sources

- [The company's filing (Inhibrx Biosciences)](https://www.sec.gov/Archives/edgar/data/0002007919/000200791926000057/inhibrx-20261113.htm?ref=bullished.co) — SEC filing
- [Inhibrx Biosciences — Form 10-Q for the quarter ended 2026-09-30 (quarterly results)](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000059/inhibrx-20260930.htm?ref=bullished.co) — SEC EDGAR

### More on Inhibrx Biosciences

- [Inhibrx Has $199.5 Million In Cash As It Prepares For A Possible Cancer-Drug Launch](https://www.bullished.co/inhibrx-has-199-5-million-in-cash-as-it-prepares-for-a-possible-cancer-drug-launch-88d31d9a/)
- [Inhibrx's Cancer Drug Hits 80% Response Rate In HPV-Positive Head And Neck Tumors, More Than Double Pembrolizumab Alone](https://www.bullished.co/inhibrxs-cancer-drug-hits-80-response-rate-in-hpv-positive-head-and-neck-tumors-more-than-c422dd13/)

[All Inhibrx Biosciences (INBX) coverage →](https://www.bullished.co/tag/inbx/)